PharmaPoint: Hepatitis C Virus (HCV) Therapeutics - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Hepatitis C Virus (HCV) Therapeutics - Global Drug Forecast and Market Analysis to 2025

  • December 2016 •
  • 499 pages •
  • Report ID: 4794300 •
  • Format: PDF
PharmaPoint: Hepatitis C Virus (HCV) Therapeutics - Global Drug Forecast and Market Analysis to 2025


Hepatitis C virus (HCV) is a small, enveloped RNA virus that causes acute and chronic infections of the liver and, if left untreated, can result in fibrosis, permanent liver damage (cirrhosis), Hepatocellular carcinoma (HCC), and eventually death. A member of the Flaviviridae viral family and hepacivirus genus, HCV can be classified into six major genotypes, with many additional subtypes within each genotype. While genotype 1 (GT1) causes almost half of HCV infections, all six major genotypes (GT1-6) are prevalent worldwide.

The genetic diversity of HCV strains, even within the same host, originates from the low fidelity of the ribonucleic acid (RNA) polymerase, and is thought to account for viral resistance when HCV is treated with a single drug. During the last few years, the hepatitis C treatment landscape has experienced successive waves of revolutionary change, and is now dominated by high-performance regimens comprising a new generation direct acting antivirals (DAAs). Moreover, the hepatitis C market is set to experience a steady decline, falling from $21.7 billion in 2015 to $17.5 billion by 2025, representing a negative compound annual growth rate of 2.1%.

The report “PharmaPoint: Hepatitis C Virus (HCV) Therapeutics - Global Drug Forecast and Market Analysis to 2025” states that this deterioration in sales, which will occur across the nine major markets (9MM) of the US, France, Germany, Italy, Spain, the UK, Japan, Brazil, and China, will be due to recent advances made in hepatitis C treatment, which have resulted in high cure rates and reduced adverse effects for the vast majority of individuals with chronic hepatitis C infection.

The main market for direct-acting antivirals (DAAs) curing patients of hepatitis C in 2015 was the US, contributing to over 60% of the total market size. However, declining patient populations and unusually high DAA treatment rates in 2015 will reduce the disease prevalence in the US market to a more sustainable level, with the US contributing only 48% of sales in the 9MM by 2025.

Companies reviewed in this report: AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen / Johnson & Johnson, Merck, Roche.

- Overview of hepatitis C infections, including epidemiology, etiology, pathophysiology, regional genotype distribution, as well current routine treatment recommendations of all 9MM covered.
- Topline hepatitis C market revenue from 2015-2025. Recent acquisitions, approvals and governmental recommendations and restrictions are included in the forecast model.
- Key topics covered include dynamics in the number of prevalent cases during the forecast, market characterization, unmet needs, and company strategies.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and analysis of late-stage pipeline products. An interactive clinical and commercial analyzer tool is available.
- Analysis of the current and future market competition in the global hepatitis C marketplace. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global hepatitis C market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the hepatitis C market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

We are very sorry, but an error occurred.
Please contact if the problem remains.